“Cannabis in not an entrance drug – it is an exit drug from [pharmaceutical] narcotics.”

– Dr. Uma Dhanabalan

Veterans and their families are suffering, the Veterans Health Administration (VHA) is overwhelmed, and the established treatments for Post-Traumatic Stress related disorders (PTSD) are not sufficiently effective.

To address this problem Enigami Medical Cannabis, LLC is working with Patients Out of Time and other Supporters to conduct a National, Community based Study.

To qualify for participation:

Dr. Rebecca Craft hasgood news for female medical marijuana patients: the plant’s effectiveness in treating pain is notably higher in women. Craft, a Psychology professor and researcher at Washington State University, says that the existence ofestrogen explainsthis differenceestrogen.

Of course, it’s not all good news. Higher estrogen levels also leave women more sensitive to some of the negative side effects.Craft highlights much more potent marijuana as a catalyst for the study.

“Marijuana is very different than it was 40 years ago,” she said. “It’s much higher in THC and lower in cannabidiol (CBD), so a little bit goes a very long way.”

More than 1.5 billion people in the world and an estimated 116 million Americans regularly suffer from chronic pain, and they're typically prescribed opiate pain relievers to manage their symptoms. But what happens when patients supplement their opiate pain relievers with cannabis?

A new study published in the journal Current Biology has identified differences in the way people with autism respond to smells, suggesting a "sniff test" could be used for early diagnosis of the condition.

Researchers say a 'sniff test' may be a feasible way to diagnose autism early, after finding children with the disorder have different sniff responses to those without autism.

Think of a pleasant smell - a bunch of flowers, for example. You would likely take a big sniff in order to inhale the floral aroma. When it comes to bad smell, however, you would restrict the airflow in your nose to avoid inhaling it.

Opioid painkiller addiction and accidental overdoses have become far too common across the United States. To try to identify who is most at risk, Mayo Clinic researchers studied how many patients prescribed an opioid painkiller for the first time progressed to long-term prescriptions. The answer: 1 in 4. People with histories of tobacco use and substance abuse were likeliest to use opioid painkillers long-term.

New treatments for depression and experiments which might help explain human consciousness will be put at risk if the bill banning legal highs is passed, researchers have warned.

In an open letter to Theresa May, leading British scientists urged the home secretary to add an exemption for "research pharmaceuticals being used to develop new medicines or progress neuroscience research", so that new treatments and experiments were not brought to a halt by the bill.

While cannabis alters the functions of neurobiological circuits controlling appetite, its effect on weight gain is complex since several factors appear to be involved, says Didier Jutras-Aswad, University of Montreal professor and researcher at the CHUM Research Centre. "It is known -- and often reported by users -- that cannabis causes temporary increase in appetite. As to whether it actually causes weight gain in the long term, the available data is limited. The question is all the more difficult to answer since many other factors can influence weight. For instance, cannabis use may be associated with cigarette smoking, which also alters appetite, and many effects of cannabis vary by gender and level of use.

A new study revealed that there was “moderate-quality evidence” to support the use of cannabinoid compounds for the treatment of chronic pain and spasticity. The same report also found that there was “lower-quality evidence” suggesting that cannabinoids were associated with improvements in nausea and vomiting chemotherapy, sleep disorders and Tourette syndrome.

Published in the Journal of the American Medical Association (JAMA), a peer-reviewed medical produced by the American Medical Association (AMA), the analysis reviewed 79 trials that fit the criteria for assessment. These studies included 6,462 participants.